Medicare Part D coverage · deflazacort · RxCUI 2719198
deflazacort 22.75 MG/ML Oral Suspension [Pyquvi]
Per the CMS 2026 Part D formulary file, deflazacort 22.75 MG/ML Oral Suspension [Pyquvi] is covered by 648 Medicare Part D plans (12.8% of enrollable products), averaging Tier 3.5, with prior authorization required on 100% of covering formularies.
- 12.8%
- Plan coverage
- 648
- Plans covering
- T3.5
- Avg tier
- 100%
- Prior auth required
What the CMS Formulary Data Shows for deflazacort 22.75 MG/ML Oral Suspension [Pyquvi]
Per the CMS 2026 Part D formulary file, deflazacort 22.75 MG/ML Oral Suspension [Pyquvi] (RxNorm concept RXCUI 2719198, generic name deflazacort) appears on 8 distinct formulary files spanning 648 Medicare Part D plan offerings - 12.8% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 3.5.
Real-world access to deflazacort 22.75 MG/ML Oral Suspension [Pyquvi] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 99 Part D beneficiaries filled deflazacort 22.75 MG/ML Oral Suspension [Pyquvi] in 2023, with total plan-and-beneficiary spending of $15,369,330 and an average per-beneficiary annual cost of $155,245.76. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry deflazacort 22.75 MG/ML Oral Suspension [Pyquvi] today.
Coverage Details
- Formularies covering
- 8
- Plans covering
- 648
- Coverage rate
- 12.8%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 100% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 99
- Total spending
- $15,369,330
- Avg per beneficiary
- $155,245.76
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering deflazacort 22.75 MG/ML Oral Suspension [Pyquvi]
100 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| CalOptima Health OneCare Complete (HMO D-SNP) | Orange County Health Authority | T1 | Yes | $0 | CA |
| Mass General Brigham SCO (HMO D-SNP) | Mass General Brigham Health Plan, Inc | T1 | Yes | $0 | MA |
| Mass General Brigham One Care (HMO D-SNP) | Mass General Brigham Health Plan, Inc | T1 | Yes | $0 | MA |
| UHC Dual Complete IA-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T5 | Yes | $0 | IA |
| UHC Dual Complete MO-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T5 | Yes | $0 | MO |
| UHC Dual Complete NE-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T5 | Yes | $0 | NE |
| UHC Dual Complete KS-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T5 | Yes | $0 | KS |
| UHC Dual Complete MO-S3 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T5 | Yes | $0 | MO |
| UHC Dual Complete KS-Q1 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T5 | Yes | $0 | KS |
| UHC Dual Complete TN-S001 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T5 | Yes | $0 | TN |
| UHC Dual Complete TN-Y001 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T5 | Yes | $0 | TN |
| UHC Dual Complete TN-Y2 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T5 | Yes | $0 | TN |
| AARP Medicare Advantage from UHC MI-0001 (PPO) | Unitedhealthcare Insurance Company | T5 | Yes | $0 | MI |
| UHC Dual Complete NM-Y1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T5 | Yes | $0 | NM |
| UHC Dual Complete NM-S1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T5 | Yes | $0 | NM |
| UHC Dual Complete NM-V1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T5 | Yes | $0 | NM |
| UHC Dual Complete AZ-S001 (HMO-POS D-SNP) | Arizona Physicians IPA, Inc. | T5 | Yes | $0 | AZ |
| UHC Dual Complete AZ-Y001 (HMO-POS D-SNP) | Arizona Physicians IPA, Inc. | T5 | Yes | $0 | AZ |
| UHC Dual Complete VA-Y4 (PPO D-SNP) | Care Improvement Plus South Central Insurance Co. | T5 | Yes | $0 | VA |
| AARP Medicare Advantage from UHC AL-0001 (HMO-POS) | Unitedhealthcare OF THE Midlands, Inc. | T5 | Yes | $0 | AL |
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is deflazacort 22.75 MG/ML Oral Suspension [Pyquvi] covered by Medicare Part D?
Yes, deflazacort 22.75 MG/ML Oral Suspension [Pyquvi] is covered by 648 Medicare Part D plans (12.8% of all Part D formularies).
What tier is deflazacort 22.75 MG/ML Oral Suspension [Pyquvi] on Medicare Part D plans?
deflazacort 22.75 MG/ML Oral Suspension [Pyquvi] averages Tier 3.5 across Part D plans, ranging from Tier 1 to Tier 5.
Does deflazacort 22.75 MG/ML Oral Suspension [Pyquvi] require prior authorization?
100% of Part D formularies require prior authorization for deflazacort 22.75 MG/ML Oral Suspension [Pyquvi]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on deflazacort 22.75 MG/ML Oral Suspension [Pyquvi]?
In 2023, total Medicare Part D spending on deflazacort 22.75 MG/ML Oral Suspension [Pyquvi] was $15,369,330, covering 99 beneficiaries. The average spend per beneficiary was $155,245.76.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- lomustine 40 MG Oral Capsule T3.5
- 1 ML denosumab 60 MG/ML Prefilled Syringe [Prolia] T3.5
- tretinoin 0.001 MG/MG Topical Gel T3.5
- ethacrynic acid 25 MG Oral Tablet T3.5
- daridorexant 25 MG Oral Tablet [Quviviq] T3.5
- 24 HR canagliflozin 150 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [Invokamet] T3.5
Similar prior-authorization rate
- sodium phenylbutyrate 0.483 MG/MG Oral Pellet [Pheburane] 100% PA
- azathioprine 50 MG Oral Tablet 100% PA
- formoterol fumarate 0.01 MG/ML Inhalation Solution [Perforomist] 100% PA
- lusutrombopag 3 MG Oral Tablet [Mulpleta] 100% PA
- 12 HR tapentadol 100 MG Extended Release Oral Tablet [Nucynta] 100% PA
- {14 (24 HR lamotrigine 100 MG Extended Release Oral Tablet [Lamictal]) / 7 (24 HR lamotrigine 200 MG Extended Release Oral Tablet [Lamictal]) / 14 (24 HR lamotrigine 50 MG Extended Release Oral Tablet [Lamictal]) } Pack [Lamictal XR Green Patient Titration Kit (for Patients Taking Carbamazepine, Phenytoin, Phenobarbital, or Primidone, and Not Taking Valproate)] 100% PA